Delphine Topart
Centre Hospitalier Universitaire de Montpellier(FR)Centre Hospitalier Universitaire de Montpellier(FR)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Bladder and Urothelial Cancer Treatments, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma(2021)723 cited
- → Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial(2021)635 cited
- → Frequent expression of PD‐L1 on circulating breast cancer cells(2015)369 cited
- → Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial(2022)267 cited
- → Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma(2024)255 cited
- → Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program(2020)52 cited